Why You Molecular Marker Testing On Suspicious thyroid biopsies Can Save you a Surgery.

Why You Molecular Marker Testing On Suspicious thyroid biopsies Can Save you a Surgery.

Why You Molecular Marker Testing On Suspicious thyroid biopsies Can Save you a Surgery.

Why You Molecular Marker Testing On Suspicious thyroid biopsies Can Save You a Surgery.

Comments: No patient should go to surgery with an indeterminate result on a thyroid biopsy in 2017. The use of marker testing on needle biopsy needle washout samples and even on the slides after the biopsy ( microdissection of nuclei acids ) can reduce the surgeries in benign nodules by 85%. Do you really want to allow you local surgeon to take you in the hospital,operate, and during your recovery tell you it is benign when you could have known that by having marker testing. Get another opinion bey you submit to surgery. Interpace has a unique system of markers and a reflex classifier on needle washout and by microdissection of prior needle biopsy slides. This is one of the best ways to save yourself a surgery. They have 85% reduction in surgery in benign nodules when the biopsy gave indeterminate results and their results were benign.

imgres-4-1-300x36

RosettaGX has a system to do markers on slides as well.

images

Richard Guttler MD,FACE,ECNU

thyroid.com

 

ROLE OF MOLECULAR MARKERS IN THYROID NODULE MANAGEMENT: THEN AND NOW.

images
World expert in marker testing gives his views in this paper. CBL labs have their marker testing developed by DR.Nikiforov.
“Over the last two decades, our understanding of the genetic mechanisms of thyroid cancer has dramatically expanded, such that most thyroid cancers now have known gene driver events. This knowledge provides the basis for establishing and further improving molecular tests for thyroid nodules and cancer and for the introduction of new entities such as non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). The progress with molecular tests for thyroid nodules started in the 1990’s from demonstrating feasibility of detecting various molecular alterations in fine-needle aspiration (FNA) material collected from thyroid nodules. It followed by the introduction of first single gene mutational markers, such as BRAF, and small mutational panel into clinical practice in the mid 2000’s. Currently, several more advanced molecular tests are available for clinical use. They are based on multiple molecular markers and have increasing impact on the clinical management of patients with thyroid nodules.”

CONCLUSION:

“The evolution of molecular tests for thyroid nodules followed the discovery of various diagnostic and prognostic molecular markers of thyroid cancer that can be applied to thyroid FNA samples to inform more individualized management of these patients.”

Add Your Comment

Contact Info
1328 16th Street, Santa Monica, CA 90404
Monday – Friday
9:00 AM to 5:00 PM
(310) 393-8860